Indian generic version of Enasidenib drug price reference

Enasidenib As a targeted drug for IDH2 mutant acute myeloid leukemia (AML), it has been widely used overseas and has been on the market in the United States, Europe, Japan and other places for many years. However, as of 2025, there is no officially approved generic version of ensidipine in the Indian market. At present, the drug may be in the research and development and evaluation stages in India, and there is no approved manufacturer or finished drug for sale yet.

In the international drug trade, India is often regarded as an important source for patients to obtain high-priced innovative drug alternatives due to its mature generic drug system and cost control capabilities. However, ensidipine is a newer molecularly targeted drug, and its patent protection is still valid. Therefore, Indian companies have not publicly produced or exported generic versions of the drug. According to overseas pharmaceutical administration data, the generic versions currently on the market are mainly launched by Laos Lucius Pharmaceutical Factory, Daxiong Pharmaceutical, United Pharmaceuticals and pharmaceutical companies in some ASEAN countries. The common specifications are 50mg×30 tablets or 100mg×30 tablets. The price range fluctuates greatly depending on the region and exchange rate.

Referring to foreign market prices, the monthly treatment cost of generic drugs in the United States can be as high as several thousand dollars, while the price of generic drugs in Laos and some Southeast Asian regions is about one-third to one-fifth of the original drug. Despite this, Indian pharmaceutical companies have shown their willingness to develop, and some manufacturers are applying for API production licenses. Once the patent period expires or a compulsory license is obtained, the market price of the Indian version of ensidipine is expected to be significantly lower than the original drug, which is expected to provide higher accessibility to AML patients around the world.

From a patient's perspective, before waiting for the official launch of Indian generic drugs, if you need to use the drug, it is a safer way to import overseas original drugs or generic drugs from the ASEAN region through formal channels.

Reference materials:https://www.idhifa.com/